Last updated on December 20th, 2017 at 12:19 pm
Today, the pharmaceutical market offers a large variety of anti-obesity drugs. One of such medications is Suprenza, which has its own characteristics and properties.
Suprenza is used for the treatment of obesity and overweight in adults and adolescents of 16 years of age or older. This anti-obesity drug is prescribed to patients based on their body mass index index (BMI).
Target groups, which can be prescribed Suprenza tablets
Administration of Suprenza helps to quickly and permanently reduce appetite. The drug activates the center of saturation and suppresses hunger center located in the brain. Thus, the anti-obesity drug deceives your body and makes it believe that it is not hungry.
Suprenza is the only Phentermine-based anti-obesity drug, which is produced in the form of orally disintegrating tablets (ODT).
With this dosage form, tablets are quickly absorbed and enter the blood stream.
Suprenza ODT are available in three dosages, which allows selecting the effective therapeutic dose for each obese person, given its features and clinical response to treatment:
round yellow tablets with blue inclusions
round yellow tablets
round white tablets with blue inclusions
Posology and method of administration
Throughout the entire treatment course, it is recommended to combine Suprenza tablets with adequate exercise and a low calorie diet.
Suprenza ODT are taken once daily in the morning, without regard to meals. Pills should be taken with dry hands and placed on the tongue, where it gradually dissolves within a few minutes. After complete dissolution of the tablet, patients are allowed to have a glass of water.
The recommended starting dose is 15 mg to 30 mg per day. Where the anorectic effect is expressed insufficiently, the dose should be increased to 37.5 mg.
Serious adverse events are rare and depend on the individual patient’s characteristics and age. Those at risk are older patients and patients with renal impairment.
The most common minor adverse events, occurring during Suprenza course, are nausea, headache, gastrointestinal disturbances, insomnia, increased blood pressure and heart rate.
Severe adverse effects may manifest through chest pain, depression, primary pulmonary hypertension, and shortness of breath. Patients who experience these symptoms should stop taking the drug and seek help from a doctor.
Precautions and warnings
Do not combine Suprenza with other medications and supplements, used for weight loss. During the treatment course, caution should be used when taking antidepressants that inhibit the reuptake of serotonin (Luvox, Zoloft, Prozac, Paxil).
Suprenza ODT are contraindicated to combine with MAO inhibitors (Nardil, Zelapar). Combination of these drugs may lead to hypotonic crisis.
The drug should not be taken by pregnant women and during breastfeeding. Hypersensitivity to the components of Suprenza ODT is a contraindication for use.